50.13 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Exelixis Inc
EXELNASDAQ • USD
50.25
↗ 0.12 (0.24%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
50.25
↗ 0.12 (0.24%)
Market: CLOSED
Open?$51.09
High?$51.31
Low?$49.59
Prev. Close?$50.13
Volume?2.1M
Avg. Volume?2.7M
VWAP?$50.13
Rel. Volume?0.76x
Bid / Ask
Bid?$48.50 × 100
Ask?$52.00 × 700
Spread?$3.50
Midpoint?$50.25
Valuation & Ratios
Market Cap?12.6B
Shares Out?251.4M
Float?251.4M
Float %?96.8%
P/E Ratio?15.12
P/B Ratio?6.51
EPS?$3.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees
1.1K
Market Cap
12.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2000-04-11
Address
1851 HARBOR BAY PARKWAY
ALAMEDA, CA 94502
Phone: (650) 837-7000
ALAMEDA, CA 94502
Phone: (650) 837-7000
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.26Strong
Quick Ratio?3.19Strong
Cash Ratio?0.61Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score78/100
P/E?15.1CHEAP▾
P/B?6.51FAIR▾
P/S?5.30FAIR▾
P/FCF?13.8CHEAP▾
EV/EBITDA?12.6FAIR▾
EV/Sales?5.21FAIR▾
Returns & Efficiency
ROE?43.1%STRONG▾
ROA?32.1%STRONG▾
Cash Flow & Enterprise
FCF?$912.2M
Enterprise Value?$12.4B
Fundamentals ratios updated end of day